secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001193125-25-083523
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea appoints Howard Berman to board, authorizes $25M buyback after activist settlement
--------------------------------------------------------------------------------

- Howard H. Berman (Coya Therapeutics founder) appointed as Class III director effective after 2025 annual meeting; will serve as observer until then.
- Agreement with activist investors Bradley Radoff and Michael Torok: slate withdrawn, standstill and voting commitments through mid-2026.
- Franklin Berger will retire from board after his Class I term expires at 2027 annual meeting.
- Board authorized up to $25M share repurchase program; strategic alternatives review with Evercore ongoing.
- Preliminary cash, cash equivalents and marketable securities as of March 31, 2025: $425.4 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/d915073d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-083523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer